Reducing differences in immune-based cancer treatment outcomes in Detroit
Disparities in Immuno-oncology Outcomes in Detroit (DIODE)
This project looks at why immune therapies like HER2-targeted antibodies work differently for people with HER2-positive breast cancer in Detroit, especially in higher-risk groups.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-11184198 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers will compare the genes and immune features of tumors from Detroit residents with HER2-positive breast cancer to understand why some people respond less well to HER2 antibody treatment. They will analyze tumor and immune cells, with a focus on macrophage function and genetic regulators of immune tolerance and tumor immunity. The team will include patients from diverse ancestry groups in metropolitan Detroit and build local research partnerships through a planning infrastructure to guide future clinical strategies.
Who could benefit from this research
Good fit: People living in metropolitan Detroit with HER2-positive breast cancer, particularly those from groups with historically poorer outcomes, are the ideal candidates for this effort.
Not a fit: Patients without HER2-positive tumors or those who do not live in the Detroit area may not directly benefit from this specific project.
Why it matters
Potential benefit: If successful, this work could help tailor HER2 antibody treatments to patient ancestry and immune profiles and improve outcomes for high-risk Detroit patients.
How similar studies have performed: Prior research shows immune genetics can affect response to HER2 therapies, but identifying ancestry-specific regulators of macrophage response is a newer and less-tested area.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Purrington, Kristen S. — Wayne State University
- Study coordinator: Purrington, Kristen S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.